These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 27354668)

  • 1. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
    Zhang S; Liu J; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):623-628. PubMed ID: 28935016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
    Buchbinder EI; Desai A
    Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective.
    Walia HK; Sharma P; Singh N; Sharma S
    Curr Treat Options Oncol; 2022 Feb; 23(2):268-294. PubMed ID: 35226309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus ipilimumab in non-small-cell lung cancer.
    Reck M; Borghaei H; O'Byrne KJ
    Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
    Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
    Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
    Schmid S; Mauti LA; Friedlaender A; Blum V; Rothschild SI; Bouchaab H; Frösch P; Britschgi C; König D; Wannesson L; Janthur WD; Schär S; Demmer I; Addeo A; Jochum W; Früh M
    Cancer Immunol Immunother; 2020 Aug; 69(8):1605-1613. PubMed ID: 32307579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade in small cell lung cancer.
    Tay RY; Heigener D; Reck M; Califano R
    Lung Cancer; 2019 Nov; 137():31-37. PubMed ID: 31525648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.